USA: A new drug-eluting balloon (DEB) may offer a safer and equally effective alternative to conventional metallic stents for patients with coronary in-stent restenosis (ISR) , according to the results of the SELUTION4ISR Trial , an international study led by researchers at Mount Sinai Hospital, New York. The findings, presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference in San Francisco, mark a major advancement in interventional cardiology. ISR is a common complication where a previously treated coronary artery narrows again following stent implantation. The standard approach to managing ISR involves inserting an additional drug-eluting stent (DES) or using balloon angioplasty. However, adding more stent layers can complicate future procedures and

See Full Page